D-Lina M 2.5 mg+850 mg (Tablet)

Therapeutic Class

• Combination Oral hypoglycemic preparations

Indications

• Adjunct to diet and exercise
• Improving glycemic control
• Adults with type 2 diabetes mellitus

Pharmacology

• Inhibitor of DPP-4
• Increases concentrations of incretin hormones
• Stimulates insulin release from pancreatic beta cells
• Decreases glucagon secretion from pancreatic alpha cells
• Lowers basal and postprandial plasma glucose
• Decreases hepatic glucose production
• Improves insulin sensitivity

Dosage & Administration

• Individualized dosage based on effectiveness and tolerability
• Maximum recommended doses for immediate and extended release tablets
• Gradual dose escalation to reduce gastrointestinal side effects
• Recommended starting doses for different patient groups
• Instructions for switching from individual components to combination tablet

Interaction

• Potential interaction with cationic drugs
• Potential for competition for renal tubular transport systems
• Possible metabolic acidosis with carbonic anhydrase inhibitors
• Effect of P-glycoprotein and CYP3A4 enzyme inducers on Linagliptin
• Drugs affecting glycemic control and their impact

Contraindications

• Contraindicated in renal impairment
• Contraindicated in acute or chronic metabolic acidosis
• Contraindicated in hypersensitivity to Linagliptin or Metformin Hydrochloride

Side Effects

• Most common: nasopharyngitis and diarrhea
• Increased risk of hypoglycemia with sulfonylureas

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• Caution in administration to lactating mothers

Precautions & Warnings

• Discontinuation and supportive therapy in case of lactic acidosis
• Postmarketing reports of acute pancreatitis
• Temporary discontinuation in certain medical procedures
• Monitoring of Vitamin B12 levels
• Symptoms and precautions for lactic acidosis
• Instructions for alcohol, other medicines, counseling, travel, and emergencies
• Warnings about hypoglycemia

Overdose Effects

• Supportive measures in case of overdose
• Removal of unabsorbed material from the gastrointestinal tract
• Clinical monitoring and supportive treatment
• Dialyzability of Metformin Hydrochloride
• Clinical adverse drug reactions with Linagliptin overdose
• Outcome of Metformin Hydrochloride overdose

Storage Conditions

• Cool & dry place (below 30°C)
• Protected from light & moisture
• Keep out of the reach of children

Related Brands

• Linadus M XR 5 mg+1000 mg (Tablet (Extended Release)) - opsonin-pharma-ltd
• LG-M 2.5 mg+500 mg (Tablet) - silco-pharmaceutical-ltd
• Ligazid MX 5 mg+1000 mg (Tablet (Extended Release)) - eskayef-pharmaceuticals-ltd
• Renolina M 2.5 mg+850 mg (Tablet) - dbl-pharmaceuticals-ltd
• Renolina M 2.5 mg+500 mg (Tablet) - dbl-pharmaceuticals-ltd